BR112018067416A8 - Composições para o tratamento da candidíase - Google Patents

Composições para o tratamento da candidíase

Info

Publication number
BR112018067416A8
BR112018067416A8 BR112018067416A BR112018067416A BR112018067416A8 BR 112018067416 A8 BR112018067416 A8 BR 112018067416A8 BR 112018067416 A BR112018067416 A BR 112018067416A BR 112018067416 A BR112018067416 A BR 112018067416A BR 112018067416 A8 BR112018067416 A8 BR 112018067416A8
Authority
BR
Brazil
Prior art keywords
candidiasis
treatment
compositions
lactobacilli
cfu
Prior art date
Application number
BR112018067416A
Other languages
English (en)
Other versions
BR112018067416A2 (pt
Inventor
Nivoliez Adrien
Original Assignee
Biose
Nexbiome Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biose, Nexbiome Therapeutics filed Critical Biose
Publication of BR112018067416A2 publication Critical patent/BR112018067416A2/pt
Publication of BR112018067416A8 publication Critical patent/BR112018067416A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A presente invenção se refere a uma composição compreendendo como agente ativo antifúngico pelo menos 2 x 1010 CFU de lactobacilos e um composto contendo enxofre para uso como um tratamento de primeira linha para candidíase e candidíase recorrente.
BR112018067416A 2016-03-01 2017-03-01 Composições para o tratamento da candidíase BR112018067416A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1651717 2016-03-01
FR1651717A FR3048361B1 (fr) 2016-03-01 2016-03-01 Compositions pour le traitement des candidoses
PCT/EP2017/054701 WO2017148975A1 (fr) 2016-03-01 2017-03-01 Compositions pour le traitement des candidoses

Publications (2)

Publication Number Publication Date
BR112018067416A2 BR112018067416A2 (pt) 2018-12-26
BR112018067416A8 true BR112018067416A8 (pt) 2022-08-30

Family

ID=56411709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067416A BR112018067416A8 (pt) 2016-03-01 2017-03-01 Composições para o tratamento da candidíase

Country Status (11)

Country Link
US (2) US11197899B2 (pt)
EP (1) EP3423072B1 (pt)
CN (1) CN109069557A (pt)
BR (1) BR112018067416A8 (pt)
CA (1) CA3012557A1 (pt)
ES (1) ES2951677T3 (pt)
FR (1) FR3048361B1 (pt)
HU (1) HUE062933T2 (pt)
PL (1) PL3423072T3 (pt)
RU (1) RU2732244C2 (pt)
WO (1) WO2017148975A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937324B (zh) * 2018-01-10 2020-01-21 中国科学院微生物研究所 一株卷曲乳杆菌及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK242083D0 (da) 1983-05-27 1983-05-27 Hansens Chr Bio Syst Vaginalkapsler
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
DK0956858T3 (da) * 1998-04-30 2002-01-28 Vesely Renata Maria Cavaliere Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
EP1303300B1 (en) * 2000-06-19 2010-08-11 Hunter Immunology Limited Compositions and methods for treatment of candidiasis
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
WO2006045347A1 (en) 2004-10-22 2006-05-04 Medinova Ag Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens
US8329447B2 (en) * 2008-12-12 2012-12-11 Osel, Inc. Strain of Lactobacillus crispatus
ITRM20110477A1 (it) * 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
FR2992973B1 (fr) * 2012-07-09 2015-12-18 S P M D Nouvelle souche de lactobacillus crispatus
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
FR3018193B1 (fr) * 2014-03-10 2017-09-08 Probionov Comprime vaginal muco-adhesif a liberation prolongee
MX2016016773A (es) * 2014-07-01 2017-06-30 Probi Usa Inc Comprimidos probióticos bicapa de doble liberacion.

Also Published As

Publication number Publication date
PL3423072T3 (pl) 2023-10-02
RU2018132814A (ru) 2020-04-01
RU2018132814A3 (pt) 2020-04-09
EP3423072B1 (fr) 2023-06-07
FR3048361B1 (fr) 2020-12-18
US11197899B2 (en) 2021-12-14
FR3048361A1 (fr) 2017-09-08
ES2951677T3 (es) 2023-10-24
CN109069557A (zh) 2018-12-21
BR112018067416A2 (pt) 2018-12-26
US20220125863A1 (en) 2022-04-28
RU2732244C2 (ru) 2020-09-14
WO2017148975A1 (fr) 2017-09-08
EP3423072A1 (fr) 2019-01-09
US20190046593A1 (en) 2019-02-14
CA3012557A1 (fr) 2017-09-08
EP3423072C0 (fr) 2023-06-07
HUE062933T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
UY37789A (es) Nuevos derivados de azaquinolina
DOP2020000023A (es) Nuevos derivados de quinolina
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
AU2016245785A8 (en) Synergistic preservative compositions
UY36254A (es) 2 – (morfolin-4-il) – 1,7-naftiridinas
WO2017178892A3 (en) Selenium disulfide compositions for use in treating meibomian gland dysfunction
CO2020001242A2 (es) Dihidrooxadiazinonas
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
BR112018010903A2 (pt) composições compreendendo bacillus licheniformis e bacillus subtilis e métodos de uso para o controle de nematóides
CO2020013876A2 (es) Nuevos derivados de quinolina
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112022004341A2 (pt) Composições tópicas
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
BR112017023448A2 (pt) composições anti-fitopatogênicas
BR112018067416A8 (pt) Composições para o tratamento da candidíase
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
PH12016501448A1 (en) Antifungal composition
UY36983A (es) Pirazolopiridinaminas sustituidas
UA120448U (uk) Фунгіцидна композиція
BR112021015795A8 (pt) Composição

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: NEXBIOME THERAPEUTICS (FR)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]